UKUK

New access to an unstable receptor

11.06.2011

London – UK-headquartered pharma major AstraZeneca and Heptares Therapeutics have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). Under the terms of the agreement, AstraZeneca has worldwide commercial rights to product candidates emerging from the collaboration. Heptares will receive US$6.25m in up-front R&D funding, and will be eligible for US$181.75m in possible milestone payments and royalties on the sale of any products. GPCRs are among the largest and most important family of drug targets. However, their instability has often prevented pharmaceutical researchers from understanding their molecular structures, and hampered efforts to design medicines aimed at GPCR targets. Now Heptares has developed a proprietary technology (StaR®) that allows stabilised versions of GPCRs to be investigated. Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders. Since its spin-off from the UK Medical Research Council (MRC) in 2007, Heptares has raised more than US$35m from venture investors formed partnerships with Shire, Takeda, and Novartis.

UKUK

23.08.2011

London - GlaxoSmithKline has invested about €1.5m to take a 25.4 percent stake in Autifony Therapeutics, a British biotechnology company spun out of GSK to research treatments for tinnitus and hearing loss. Autifony’s other...

UKUK

19.08.2011

Brussels – While worldwide stock exchanges took a beating in late July and early August, European biotech stocks plunged even more. Stocks of majors like Roche, Novartis and GSK lost more than 10% in the first week of the month,...

Austria, UKUK

17.08.2011

London/Pasching –GE Healthcare vamps up its biopharmaceutical capabilities. The U.K. based unit of the U.S. technology giant General Electric, announced that it has reached an agreement to acquire the Austrian PAA Laboratories....

UKUK

16.08.2011

London – The International Multiple Sclerosis Genetics Consortium, led by the Universities of Cambridge and Oxford and funded by the Wellcome Trust, has identified 29 new genetic variations linked to multiple sclerosis (MS). The...

UKUK

16.08.2011

London – A consortium led by British gene medicince company Ark Therapeutics Group plc has received a EUR5.3m grant from the European Commission’s 7th Framework Programme to fund research to combine Ark’s technology covering...

UKUK

09.08.2011

London - Patents on biomarkers are necessary to encourage innovation and investment in the UK DNA diagnostics market. This is the conclusion of a report from the UK Human Genetics Commission. The paper "Intellectual Property and...

UKUK

15.07.2011

London/Rockville - GlaxoSmithKline and its American partner Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorisation for belimumab (Benlysta) as an add-on therapy in adult...

UKUK

07.07.2011

The British analytics specialist LGC Ltd. will buy its peer, KBioscience, for an undisclosed sum. The acquisition of KBioscience brings LGC expertise in genotyping services, chemistry and complements its genomic services...

Displaying results 31 to 40 out of 396

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/3/article/new-access-to-an-unstable-receptor.html

Product of the week

Products

Events

All Events

Current issue

All issues